Kura Oncology (KURA: NASDAQ) Investor Relations Material

Overview

Kura Oncology, Inc. - A Key Player in the Cancer Treatment Industry Kura Oncology, Inc. is a prominent clinical-stage biopharmaceutical company, primarily focused on developing innovative therapies for patients suffering from various forms of cancer across the United States. With its extensive pipeline of small molecule product candidates, Kura Oncology is dedicated to bringing reliable and robust solutions to address the unmet medical needs of cancer patients. One of the company's lead product candidates is ziftomenib - a small molecule inhibitor that targets the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction. Ziftomenib has been designed explicitly for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia, delivering outstanding results in numerous clinical trials. Another essential product from the company's arsenal is tipifarnib - an orally bioavailable inhibitor of farnesyl transferase for the treatment of solid tumors and hematologic indications - underlined as one of the most promising treatment options for cancer patients across the industry. Kura Oncology recently announced an exciting clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma. The trial targets patients whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification, which encompasses approximately 10-15% of head and neck cancer patients. Through this collaboration, Kura Oncology continues to demonstrate its commitment to delivering innovative cancer solutions. Kura Oncology, Inc. was founded in 2014, and its headquarters are based in San Diego, California. With its robust pipeline of innovative therapies and significant partnerships in place, the company is poised to make significant strides in the cancer treatment industry.